S. Caplan et al., Trafficking of major histocompatibility complex class II molecules in human B-lymphoblasts deficient in the AP-3 adaptor complex, IMMUNOL LET, 72(2), 2000, pp. 113-117
The major histocompatibility complex class II subunits (MHC-II) alpha and b
eta assemble with the invariant chain (Ii) in the endoplasmic reticulum and
are transported to endosomal-lysosomal organelles known as MHC class II co
mpartments (MIICs). Although it has been shown that two dileucine-based sig
nals in the cytosolic tail of Ii, as well as a dileucine-based signal in th
e tail of the beta chain mediate sorting to MIICs, the molecular mechanisms
by which alpha beta Ii complexes are sorted have yet to be resolved fully.
The AP-3 adaptor complex stands oat as a particularly good candidate for m
ediating this targeting because: (i) it has a proven role in the traffickin
g of membrane proteins to lysosome-related organelles; and (ii) it has the
ability to interact with dileucine-based signals in vitro. To investigate t
he potential role of AP-3 in transport of MHC-II to MIICs. we have examined
MHC-II trafficking in human B-lymphoblast lines from patients with Hermans
ky-Pudlak syndrome type 2 (HPS-2), which are deficient in the AP-3 complex.
Pulse-chase analyses revealed no significant alteration in the kinetics of
synthesis and degradation of either MHC-II subunits or Ii. Moreover, we ob
served neither impairment of the formation of compact SDS-resistant alpha b
eta dimers, nor delay in the appearance of a conformational epitope indicat
ive of a mature, Ii-free alpha beta dimer. Finally, we demonstrated that in
HPS-2 patients' cells, there was no delay in the expression of the alpha b
eta dimers on the cell surface. Thus, AP-3 does not seem to be essential fo
r normal trafficking of MHC-II. These findings have important implications
for HPS-2 patients, because they suggest that the recurrent bacterial infec
tions suffered by these patients are not likely due to impaired antigen pro
cessing and presentation by MHC-II. (C) 2000 Published by Elsevier Science
B.V. All rights reserved.